Molecular structure of Safinamide mesylate, CAS Number: 202825-46-5
Safinamide mesylate (CAS 202825-46-5)
Alternate Names:
(S)-(+)-2-[[4-(3-Fluorobenzoxy)benzyl]amino]propanamide; (S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]
Application:
Safinamide mesylate is a potent and selective MAO-B inhibitor
CAS Number:
202825-46-5
Purity:
≥98%
Molecular Weight:
398.45
Molecular Formula:
C17H19FN2O2•CH4O3S
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Safinamide is a dopamine reuptake inhibitor by being a highly selective inhibitor of MAO-B (IC50 = 98 nM. Additionally, this compound has a high affinity for Na+ channels (IC50 = 8 μM.
Safinamide mesylate (CAS 202825-46-5) References
- Safinamide in the treatment of Parkinson's disease. | Schapira, AH. 2010. Expert Opin Pharmacother. 11: 2261-8. PMID: 20707760
- The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease. | Perez-Lloret, S. and Rascol, O. 2016. Expert Rev Neurother. 16: 245-58. PMID: 26849427
- Investigational agents in the treatment of Parkinson's disease: focus on safinamide. | Malek, NM. and Grosset, DG. 2012. J Exp Pharmacol. 4: 85-90. PMID: 27186120
- Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease. | Müller, T. 2017. Expert Opin Drug Metab Toxicol. 13: 693-699. PMID: 28537214
- Safinamide mesylate, Brodalumab, Guselkumab, and Abaloparatide. | Hussar, DA. and Kotova, M. 2018. J Am Pharm Assoc (2003). 58: 123-127. PMID: 29290341
- 2018 New Drug Update. | Hussar, DA. and Finn, LA. 2018. Consult Pharm. 33: 188-198. PMID: 29609697
- Solid-State Study of the Structure, Dynamics, and Thermal Processes of Safinamide Mesylate─A New Generation Drug for the Treatment of Neurodegenerative Diseases. | Pawlak, T., et al. 2022. Mol Pharm. 19: 287-302. PMID: 34856803
- Highly Efficient Radiosynthesis and Biological Evaluation of [18 F]Safinamide, a Radiolabelled Anti-Parkinsonian Drug for Positron Emission Tomography Imaging. | Xu, Y., et al. 2022. ChemMedChem. 17: e202200472. PMID: 36068922
- Analgesic effect of safinamide mesylate in a rat model of neuropathic pain. | Kogo, Y., et al. 2023. Behav Brain Res. 452: 114555. PMID: 37355233
Inhibitor of:
DAT, MAO-B, and SLC6A2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Safinamide mesylate, 5 mg | sc-364754 | 5 mg | $90.00 | |||
Safinamide mesylate, 25 mg | sc-364754A | 25 mg | $278.00 |